BioNTech and DualityBio report positive data for trastuzumab pamirtecan

BioNTech and DualityBio reported encouraging data from a Phase II cohort of their study evaluating the efficacy of trastuzumab pamirtecan. The post BioNTech and DualityBio report positive data for trastuzumab pamirtecan appeared first on Hospital Management .